DrugPatentWatch Database Preview
Details for Biologics License Application: 761049
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Summary for BLA: 761049
| Tradename: | BAVENCIO |
| Applicant: | Emd Serono Inc |
| Ingredient: | avelumab |
| Patents: | 24 |
| Approval Date: | Apr 25, 2017 |
| Suppliers: see list | 1 |
US Patents for BLA: 761049
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emd Serono Inc | BAVENCIO | avelumab | INJECTABLE;INJECTION | 761049 | 001 | 2017-04-25 | Start Trial | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | 2035-06-26 | RX | Orphan | search |
| Emd Serono Inc | BAVENCIO | avelumab | INJECTABLE;INJECTION | 761049 | 001 | 2017-04-25 | Start Trial | ModernaTX, Inc. (Cambridge, MA) | 2035-12-23 | RX | Orphan | search |
| Emd Serono Inc | BAVENCIO | avelumab | INJECTABLE;INJECTION | 761049 | 001 | 2017-04-25 | Start Trial | ModernaTX, Inc. (Cambridge, MA) | 2036-05-18 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
